MX2007007387A - Derivados de tienopirimidina como inhibidores de fosfodiesterasa 10. - Google Patents

Derivados de tienopirimidina como inhibidores de fosfodiesterasa 10.

Info

Publication number
MX2007007387A
MX2007007387A MX2007007387A MX2007007387A MX2007007387A MX 2007007387 A MX2007007387 A MX 2007007387A MX 2007007387 A MX2007007387 A MX 2007007387A MX 2007007387 A MX2007007387 A MX 2007007387A MX 2007007387 A MX2007007387 A MX 2007007387A
Authority
MX
Mexico
Prior art keywords
phosphodiesterase
inhibitors
thienopyrimidine derivatives
useful
treating
Prior art date
Application number
MX2007007387A
Other languages
English (en)
Inventor
Allen Hopper
Ashok Tehim
Ruiping Liu
Mark Phillip Arrington
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of MX2007007387A publication Critical patent/MX2007007387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Ciertos derivados de tienopirimidina son utiles para la inhibicion de enzimas PDE10 y por consiguiente son utiles para el tratamiento de sindrome psiquiatricos o neurologicos, por ejemplo psicosis, trastorno obsesivo-compulsivo y/o enfermedad de Parkinson, asi como, por ejemplo, para el tratamiento de una enfermedad modulada por la actividad PDE10.
MX2007007387A 2004-12-23 2005-12-27 Derivados de tienopirimidina como inhibidores de fosfodiesterasa 10. MX2007007387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63817904P 2004-12-23 2004-12-23
PCT/US2005/047439 WO2006071988A1 (en) 2004-12-23 2005-12-27 Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors

Publications (1)

Publication Number Publication Date
MX2007007387A true MX2007007387A (es) 2007-08-03

Family

ID=36128394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007387A MX2007007387A (es) 2004-12-23 2005-12-27 Derivados de tienopirimidina como inhibidores de fosfodiesterasa 10.

Country Status (7)

Country Link
US (2) US7576080B2 (es)
EP (1) EP1831229A1 (es)
JP (1) JP2008525500A (es)
AU (1) AU2005321903A1 (es)
CA (1) CA2594676A1 (es)
MX (1) MX2007007387A (es)
WO (1) WO2006071988A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754890C (en) 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
CN102498100A (zh) * 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
EP2864335A1 (en) 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyranopyridone inhibitors of tankyrase
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014181336A1 (en) 2013-05-09 2014-11-13 Mitrassist Medical Ltd. Heart valve assistive prosthesis
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112017024665B1 (pt) * 2015-05-18 2023-02-23 Shenyang Sinochem Agrochemicals R&D Co., LTD Compostos pirazol substituídos contendo pirimidinila, preparação e aplicação dos mesmos
CN108358966B (zh) * 2018-03-05 2020-04-28 南京工业大学 一种靶向-增强线粒体功能药物Mito-VB3及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
NZ215481A (en) 1985-03-14 1989-11-28 Sankyo Co Phenoxyalkylaminopyrimidine derivatives and pesticidal compositions
JPH02105081A (ja) 1988-10-14 1990-04-17 Mitsubishi Electric Corp アナログ試験装置
CA2039411A1 (en) 1990-03-30 1991-10-01 Ronnie Gerald Edie Thienopyrimidine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
GB9517986D0 (en) 1995-09-04 1995-11-08 Sandoz Ltd Organic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997017843A1 (fr) 1995-11-16 1997-05-22 Dnavec Research Inc. Procede pour realiser des animaux transgeniques
CN101328186A (zh) 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
EP1018514B1 (en) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
BR0009338A (pt) 1999-03-26 2001-12-26 Astrazeneca Ab Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
CA2350992C (en) 1999-09-17 2009-06-23 Suntory Limited Preventive or therapeutic agents for myocarditis, dilated cardiomyopathy and heart failure comprising nf-kb inhibitors as active ingredients
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
US6945478B2 (en) * 2002-03-15 2005-09-20 Siemens Vdo Automotive Corporation Fuel injector having an orifice plate with offset coining angled orifices
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
SI1641803T1 (sl) 2003-06-11 2009-08-31 Xention Ltd Tienopirimidinski derivati kot inhibitorji kalijevih kanalov
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions

Also Published As

Publication number Publication date
EP1831229A1 (en) 2007-09-12
US20100010017A1 (en) 2010-01-14
AU2005321903A1 (en) 2006-07-06
CA2594676A1 (en) 2006-07-06
US20070259896A1 (en) 2007-11-08
WO2006071988A1 (en) 2006-07-06
JP2008525500A (ja) 2008-07-17
US7576080B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
MX2007007387A (es) Derivados de tienopirimidina como inhibidores de fosfodiesterasa 10.
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2005113515A8 (de) Pyrimidine als plk inhibitoren
GEP20063937B (en) Substituted pyridinones as modulators of p38 map kinase
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
MY138966A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
NO2010020I2 (es)
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007103370A3 (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007120333A3 (en) Tetracyclic kinase inhibitors
WO2005117938A3 (en) Methods of treating ocular conditions
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
WO2007023115A3 (en) P38 map kinase inhibitors and methods for using the same
WO2007022102A3 (en) Pentacyclic kinase inhibitors
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
PT1663997E (pt) 1h-azolilmetilamidas, processos para a sua produção e a sua utilização como inibidores de nitrificação
WO2002060373A3 (en) Indole derivatives and their uses as heparanase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal